Premium
TREATMENT‐DEPENDENCE OF HIGH‐RISK GENE EXPRESSION SIGNATURES IN DE NOVO FOLLICULAR LYMPHOMA
Author(s) -
Bolen C.R.,
Hiddemann W.,
Marcus R.,
Herold M.,
Huet S.,
Salles G.,
Mattiello F.,
Nielsen T.,
Mir F.,
Venstrom J.M.,
Oestergaard M.Z.
Publication year - 2019
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.7_2630
Subject(s) - medicine , follicular lymphoma , gene signature , oncology , hazard ratio , proportional hazards model , international prognostic index , bendamustine , chop , rituximab , progression free survival , chemotherapy , lymphoma , gastroenterology , confidence interval , biology , gene expression , gene , biochemistry
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom